STOCK TITAN

MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

MacroGenics, a biopharmaceutical company focused on innovative antibody-based cancer therapies, will present at the 41st Annual J.P. Morgan Healthcare Conference. Scott Koenig, M.D., Ph.D., President & CEO, will deliver a business update on January 12, 2023, at 9:45 am PT / 12:45 pm ET. The presentation can be accessed via a webcast on MacroGenics' Investor Relations webpage, with an archived replay available for 30 days. MacroGenics leverages proprietary antibody technology platforms to develop its pipeline and establish strategic collaborations.

Positive
  • None.
Negative
  • None.

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) --  

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the company will participate in the 41st Annual J.P. Morgan Healthcare Conference. Scott Koenig, M.D., Ph.D., President & Chief Executive Officer of MacroGenics, will provide a business update on Thursday, January 12, 2023, at 9:45 am PT / 12:45 pm ET.

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain an archived replay of this webcast on its website for 30 days.   

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###


FAQ

When will MacroGenics present at the J.P. Morgan Healthcare Conference?

MacroGenics will present on January 12, 2023, at 9:45 am PT / 12:45 pm ET.

Who will represent MacroGenics at the conference?

Scott Koenig, M.D., Ph.D., President & CEO of MacroGenics, will provide the business update.

How can I access the MacroGenics presentation?

The presentation can be accessed through a webcast on the Investor Relations section of MacroGenics' website.

How long will the MacroGenics webcast be available for replay?

The archived replay of the webcast will be available for 30 days.

What is the focus of MacroGenics' research?

MacroGenics focuses on developing innovative monoclonal antibody-based therapeutics for cancer treatment.

MacroGenics, Inc.

NASDAQ:MGNX

MGNX Rankings

MGNX Latest News

MGNX Stock Data

204.36M
58.33M
2.64%
93.46%
8.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
Rockville